Kairos Pharma, Ltd. (NYSE American: KAPA) has presented interim clinical findings for ENV-105, an investigational antibody targeting CD105-associated treatment resistance, at the 11th International Conference on Cancer Research and Drug Development in Houston, Texas. Announced on November 3, 2026, the presentation highlighted results from an ongoing Phase 2 study in metastatic castration-resistant prostate cancer, where the combination of ENV-105 and apalutamide produced a reported median progression-free survival of 17.7 months, compared with two months for apalutamide alone.
The difference was statistically significant, with a reported p-value of 0.0008, providing an encouraging early signal that inhibiting CD105 may help restore sensitivity to androgen receptor-directed therapy. However, Kairos has not disclosed the number of patients included in the interim analysis, the hazard ratio, confidence intervals or a comprehensive account of treatment-related adverse events. The large numerical difference therefore warrants further clinical investigation but should not be interpreted as definitive evidence of efficacy.
The company has also modified its Phase 2 development strategy to evaluate ENV-105 earlier in the course of treatment resistance. Instead of focusing exclusively on patients who have progressed after multiple androgen receptor-directed medicines, the revised study will enrol patients experiencing a prostate-specific antigen increase following initial androgen signalling inhibitor treatment. Participants will be randomised to enzalutamide alone or enzalutamide combined with ENV-105, with trial completion targeted for the fourth quarter of 2027.
Why are Kairos Pharma’s interim ENV-105 findings attracting attention in metastatic prostate cancer?
Metastatic castration-resistant prostate cancer develops when prostate cancer continues to progress despite treatment that lowers testosterone or otherwise suppresses androgen signalling. Many patients initially benefit from androgen receptor-targeted medicines, but resistance can emerge over time. This creates a continuing need for treatments capable of restoring the effectiveness of existing therapies or addressing mechanisms that allow resistant cancer cells to survive.
ENV-105 is being developed to inhibit CD105, a protein also known as endoglin, which participates in signalling processes associated with tumour biology. Kairos believes that CD105 can contribute to resistance following certain standard cancer treatments. Its clinical strategy involves combining ENV-105 with established medicines rather than developing the antibody exclusively as a standalone treatment.
The reported difference in median progression-free survival is substantial. Patients receiving ENV-105 plus apalutamide had a median of 17.7 months before disease progression or death under the study’s reported measure, compared with two months among patients receiving apalutamide alone. The comparison suggests that the combination may affect an important resistance pathway.
However, the size of the observed difference must be evaluated alongside the study population and design. Patients who have already progressed on androgen-targeted treatment may respond poorly when given another medicine from a related therapeutic class. A particularly short progression-free survival in the control group can therefore produce a large numerical difference without establishing how the combination would perform against every relevant modern treatment option.
The result is best understood as a promising hypothesis-generating signal requiring confirmation in a larger and more clearly characterised population.
How does ENV-105 target CD105 and BMP-SMAD signalling associated with treatment resistance?
CD105 is a cell-surface glycoprotein involved in transforming growth factor beta-related signalling. Its biological functions include participation in processes affecting blood vessels and cellular responses to environmental conditions. In cancer, CD105-associated pathways may influence how tumour cells interact with surrounding tissues and respond to therapeutic stress.
Kairos is investigating the relationship between CD105 and bone morphogenetic protein signalling, commonly described through the BMP-SMAD pathway. The company believes this pathway contributes to survival mechanisms that become active when certain cancer cells are exposed to androgen receptor inhibition or radiation. Blocking CD105 could potentially interfere with these adaptations.
ENV-105, also known as carotuximab, is a monoclonal antibody designed to bind CD105. Its intended role is to alter the signalling environment associated with treatment resistance and thereby improve the effectiveness of other therapies. The approach differs from developing a conventional cytotoxic medicine intended to kill cancer cells directly through one primary mechanism.
The distinction is important because the clinical benefit may depend on the combination partner and the biological characteristics of the tumour. A patient whose disease is driven primarily by another resistance mechanism may not respond in the same way. The relevant CD105 expression and signalling characteristics may also change during treatment.
Preclinical research has supported the proposed role of CD105 in resistance to androgen receptor inhibition and radiation. However, those findings cannot establish that the same mechanisms explain every clinical response observed in the Phase 2 programme. The relationship between target inhibition and patient outcomes remains under investigation.
What does 17.7-month median progression-free survival actually mean?
Progression-free survival measures the time from a defined starting point until disease progression or death, according to the trial’s assessment rules. Median progression-free survival is the time at which the estimated proportion of patients remaining free from progression reaches 50%. It is a common endpoint in oncology trials because it can provide information about treatment activity before enough time has elapsed to evaluate overall survival.
Kairos reported median progression-free survival of 17.7 months with ENV-105 plus apalutamide and two months with apalutamide alone. The p-value of 0.0008 indicates that the observed difference was statistically significant under the analysis reported by the company. However, statistical significance should be considered alongside clinical study design, sample size and uncertainty estimates.
The announcement did not disclose the number of patients included in the interim comparison. It also did not provide the hazard ratio or confidence intervals needed to evaluate the precision of the treatment effect. Without those details, it is difficult to determine how stable the median estimates are or how much they might change as additional data become available.
A median progression-free survival of 17.7 months does not mean every patient remained progression-free for that period. Some individuals may have experienced earlier progression, while others may have remained on treatment longer. The result also does not establish a survival advantage because overall survival is a different endpoint.
The lack of detailed safety and treatment exposure information creates another limitation. A combination that delays progression must also demonstrate acceptable tolerability, particularly when it is intended for patients who may already have received several previous treatments.
Why is the two-month progression-free survival in the apalutamide control group important?
The control group’s reported median progression-free survival of two months is central to interpreting the size of the difference. Patients with metastatic castration-resistant prostate cancer who have progressed following androgen receptor-targeted therapy can have limited responses to additional treatment affecting related pathways. This may help explain why an apalutamide-only control group experienced relatively rapid progression.
The specific treatment histories of the participants therefore matter considerably. Patients previously exposed to enzalutamide, abiraterone or other androgen-directed treatments may have different resistance characteristics. Their responses to apalutamide alone cannot automatically be used as a benchmark for less heavily treated populations.
A large difference against a weakly performing control regimen may still be clinically meaningful. However, its implications depend on whether that comparator reflects an appropriate treatment strategy for the enrolled population. The trial must also demonstrate that the observed advantage is reproducible and not driven by imbalances in disease characteristics.
The company has not disclosed a detailed breakdown of previous therapies in the November announcement. Consequently, the findings cannot be used to establish superiority over chemotherapy, radioligand therapy or every other treatment available for metastatic castration-resistant prostate cancer.
The control result also helps explain the company’s decision to modify the study. Evaluating ENV-105 earlier in the resistance pathway may provide clearer evidence about whether CD105 inhibition can restore or preserve responsiveness before patients develop more extensive treatment resistance.
Why has Kairos Pharma redesigned the Phase 2 trial around earlier resistance and enzalutamide?
Following the interim findings, Kairos modified the Phase 2 protocol to enrol patients earlier in their treatment course. Rather than waiting until patients have progressed after one or two additional anti-androgen therapies, the revised strategy targets individuals experiencing a rising prostate-specific antigen level after initial androgen signalling inhibitor treatment. The company believes this could increase eligibility and provide an opportunity to test ENV-105 before resistance becomes more advanced.
The redesigned study will randomise patients between enzalutamide alone and enzalutamide combined with ENV-105. This differs from the earlier comparison involving apalutamide. The change is important because clinical results generated with one combination cannot automatically establish the effectiveness of a different combination, even when the medicines act through related biological mechanisms.
The new design may also improve recruitment by broadening the eligible population. A larger and more consistent dataset could provide a stronger assessment of treatment activity. However, enrolling patients at an earlier disease stage can influence progression-free survival independently of the investigational antibody, making appropriate randomisation and balanced groups essential.
The company expects to complete the Phase 2 trial in or before the fourth quarter of 2027. This timetable remains prospective and will depend on enrolment, follow-up and study execution. The October and November announcements do not establish that the modified trial has already generated efficacy results.
The revision represents an attempt to convert an encouraging interim signal into a development strategy that can support stronger evidence. However, the protocol change also creates a challenge for interpreting results across the original and revised treatment populations.
How does enzalutamide differ from apalutamide within the ENV-105 development programme?
Both enzalutamide and apalutamide are androgen receptor inhibitors used in prostate cancer care. They interfere with signalling pathways that help drive growth in androgen-dependent tumour cells. However, their approved indications, clinical evidence and treatment settings are not identical.
The original ENV-105 combination study involved apalutamide in patients with metastatic castration-resistant disease. The revised programme will examine enzalutamide as the combination partner in a population selected according to earlier evidence of resistance. This introduces a different clinical question from the one addressed by the initial interim analysis.
If ENV-105 improves outcomes with enzalutamide, the finding could support the idea that CD105 inhibition influences resistance mechanisms shared across more than one androgen receptor-directed treatment. However, that conclusion requires data from the revised study rather than extrapolation from apalutamide. Differences in patient history and drug exposure may affect outcomes.
The shift also places additional importance on the definition of resistance. A rising prostate-specific antigen level may indicate worsening disease activity, but its interpretation depends on the broader clinical context. Investigators must use consistent criteria for progression and patient eligibility.
The modified programme could ultimately identify a more practical clinical setting for ENV-105. Nevertheless, the treatment’s role cannot be established until the revised comparator, safety and efficacy data are available.
Why could CD105 inhibition also be relevant to radiation resistance in prostate cancer?
Kairos has highlighted preclinical research suggesting that CD105 signalling may increase in response to ionising radiation. Radiation can damage cancer cells, but surviving cells may activate biological processes that help them withstand treatment-related stress. Understanding these mechanisms could support development of medicines intended to increase the effectiveness of radiotherapy.
The company has reported published preclinical findings investigating ENV-105 in radiation sensitisation models of prostate cancer. These experiments support the hypothesis that CD105-associated BMP-SMAD signalling may contribute to tumour cell survival following radiation exposure. Blocking the pathway could therefore potentially alter treatment response.
However, laboratory evidence of radiation sensitisation is not equivalent to clinical proof. Patients receiving radiotherapy may have different tumour biology, surrounding tissue exposure and safety considerations from experimental models. A treatment that increases the effect of radiation on cancer cells must also be assessed for effects on healthy tissue.
The current Phase 2 programme focuses on combining ENV-105 with androgen receptor-directed medicines. The November announcement does not disclose a new human trial demonstrating improved radiotherapy outcomes. The radiation research therefore provides additional mechanistic rationale rather than a separate established therapeutic indication.
Longer-term development could examine whether CD105 inhibition has relevance across several treatment modalities. However, pursuing additional combinations would require dedicated safety and efficacy investigations.
How does the Phase 1 lung cancer programme extend ENV-105 beyond prostate cancer?
Kairos is also evaluating ENV-105 in a Phase 1 study involving patients with epidermal growth factor receptor-driven non-small cell lung cancer. The programme reflects the company’s broader hypothesis that CD105 contributes to resistance mechanisms across different tumour types. Its research strategy is not limited to hormone-related prostate cancer.
EGFR-targeted therapies have improved outcomes for selected patients with molecularly defined lung cancer, but resistance frequently develops over time. Tumours may activate alternative signalling pathways or acquire molecular changes that reduce responsiveness to existing medicines. A drug influencing broader survival signalling could potentially have a role in combination treatment.
However, the mechanisms of resistance in EGFR-mutated lung cancer are not identical to those in prostate cancer. A favourable signal in one disease therefore cannot establish efficacy in another. Differences in tumour biology, prior therapy and the treatment partner will affect how ENV-105 should be evaluated.
The November announcement does not provide new numerical response rates, progression-free survival findings or detailed safety results from the Phase 1 lung cancer programme. Its existence supports the company’s platform strategy but does not demonstrate clinical benefit.
The Phase 1 study must first establish tolerability and identify any preliminary antitumour activity in the intended population. Further development would depend on whether the findings justify larger investigations.
What safety evidence is still needed for ENV-105 and its combination regimens?
A treatment intended to reverse resistance must demonstrate that its potential clinical benefit outweighs additional toxicity. Patients with metastatic castration-resistant prostate cancer may already face complications related to advanced disease and previous treatments. Introducing an investigational antibody adds another component to an already complex treatment plan.
CD105 participates in biological pathways beyond tumour resistance, making off-target physiological effects and tolerability important considerations. Potential safety concerns must be evaluated through actual clinical observations rather than assumed from the intended mechanism. The adverse-event profile may also depend on the accompanying androgen receptor inhibitor.
The November announcement does not disclose detailed treatment-related adverse-event rates, serious adverse events or discontinuation percentages from the prostate cancer trial. It therefore does not support a conclusion that ENV-105 is broadly safe or well tolerated. The absence of disclosed safety problems is not evidence that no adverse events occurred.
Longer treatment exposure will be relevant if the company intends to maintain ENV-105 during a substantial period of disease control. Researchers will need to examine whether adverse effects accumulate or require dose changes. Treatment interruptions could influence both patient quality of life and the durability of benefit.
Safety data will also be necessary for selecting doses and determining whether further studies should use the same administration strategy. The revised Phase 2 programme provides an opportunity to strengthen this evidence, but its results remain pending.
What does Kairos Pharma’s financial position mean for completion of the redesigned trial?
Kairos is a clinical-stage biotechnology company without an approved commercial product generating established pharmaceutical sales. Its ability to continue development therefore depends substantially on available cash, external financing and potential strategic arrangements. This creates a meaningful financial risk alongside the scientific uncertainty associated with ENV-105.
In its financial statements for the six months ended June 30, 2026, Kairos reported approximately $2.626 million in cash and cash equivalents. Its net loss for the period was $3.042 million, while operating activities used approximately $2.048 million in cash. These figures demonstrate the limited financial resources available relative to the costs of ongoing clinical development.
Management stated that recurring losses and expected future expenditure raised substantial doubt about the company’s ability to continue as a going concern. Its financial disclosures also identified the possibility of raising additional capital through equity offerings, debt or collaboration arrangements. The June cash balance should not be described as the company’s confirmed current position in November.
The redesign of the Phase 2 trial could increase the importance of financing because the company intends to enrol a larger population and continue development through 2027. Clinical site costs, drug supply, patient monitoring and data analysis all require funding. A statistically favourable interim result does not remove these obligations.
Kairos has also maintained an equity financing arrangement that could provide access to additional capital, subject to its terms and market conditions. However, selling new shares can dilute existing shareholders, and the availability of financing is not guaranteed.
For the company, funding execution is therefore closely connected to the ability to generate the clinical evidence needed for future development decisions.
How did Kairos Pharma shares perform around the cancer research presentation?
Kairos shares traded at approximately $0.51 on November 3, 2026, according to the company’s investor relations market snapshot, representing a gain of about 6.7% from the preceding close. The shares had closed at approximately $0.47 on November 2 after declining more than 10% during that session. These movements highlight substantial short-term volatility.
The stock’s reported 52-week range extended from approximately $0.42 to $7.28. This wide spread indicates that investors have assigned materially different valuations to the business over the preceding year. However, share-price comparisons must also account for changes in share capital and other financing developments.
The November 3 gain coincided with the company’s conference announcement, but that does not establish that the presentation was the sole cause. The interim efficacy figures had already been announced on October 6, meaning the market had prior access to the principal numerical findings. The November presentation was therefore largely an additional scientific communication rather than the first disclosure of the 17.7-month result.
Kairos’ valuation remains sensitive to clinical evidence and financing risk. The company must demonstrate that its drug can produce reproducible benefits while securing enough resources to complete further development. A small publicly traded biotechnology business may experience substantial share-price movements even when no new pivotal clinical data have been disclosed.
The central investment distinction is between promising interim efficacy and an approved commercial medicine. ENV-105 remains investigational, and its future revenue opportunity cannot be reliably estimated from the currently available dataset.
What must ENV-105 demonstrate before it can become a credible treatment for resistant prostate cancer?
The first requirement is reproducing a meaningful efficacy signal in the revised Phase 2 study. The reported 17.7-month median progression-free survival is encouraging, but the small amount of disclosed supporting information limits independent assessment. A larger dataset with clearly reported sample sizes, hazard ratios and confidence intervals will be essential.
The second requirement is showing that the treatment effect remains relevant when ENV-105 is combined with enzalutamide in an earlier resistance setting. The company cannot assume that results generated with apalutamide will apply equally to another androgen receptor inhibitor. The revised study must establish its own clinical evidence.
Safety will remain equally important. Researchers must determine whether the addition of ENV-105 produces adverse events that influence treatment continuation or patient wellbeing. A treatment offering longer disease control must still demonstrate an acceptable overall benefit-risk profile.
The fourth requirement is establishing a feasible regulatory development pathway. Even a successful Phase 2 study may need to be followed by larger confirmatory research. The FDA will evaluate the complete evidence package rather than rely solely on the magnitude of one interim progression-free survival comparison.
Finally, Kairos must secure sufficient capital to continue operating and complete the planned studies. The company’s disclosed financial position creates a meaningful constraint, making financing and clinical progress closely connected.
Kairos Pharma has generated an encouraging interim signal for ENV-105 in metastatic castration-resistant prostate cancer and is attempting to translate that finding into a stronger development strategy. The substantial difference in reported progression-free survival supports the investigation of CD105 as a resistance mechanism, but the absence of detailed cohort and safety information leaves important questions unanswered.
The next decisive milestone will be whether the redesigned Phase 2 trial demonstrates a reproducible advantage using enzalutamide in patients with earlier treatment resistance. Until those results are available, ENV-105 remains a promising but unproven approach to overcoming prostate cancer treatment resistance.
